1 Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors

2 Identification of Terfenadine as an Inhibitor of Human CD81-Receptor HCV-E2 Interaction: Synthesis and Structure Optimization

3 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

4 Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

5 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

6 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

7 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

8 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

9 Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

10 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

11 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

12 Cyclophilin A allows the allosteric regulation of a structural motif in the disordered domain 2 of NS5A and thereby fine-tunes HCV RNA replication.

13 The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

14 Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection

15 Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

16 Cognitive impairments in HCV infection: From pathogenesis to neuroimaging.

17 Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study

18 A Framework for Prediction of Response to HCV Therapy Using Different Data Mining Techniques

19 Temporal Changes and Regional Variation in Acceptance of HCV-viremic Livers.

20 Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.

21 New Insights into the Rational Use of HCV+ Organs Worldwide.

22 Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.

23 Improving the aqueous solubility of HCV-E2 glycoprotein epitope mimics by cyclization using POLAR hinges.

24 Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

25 FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.

26 The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK.

27 Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients

28 Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.

29 Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection

30 The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response

31 Immuno-MALDI MS dataset for improved detection of HCVcoreAg in sera

32 Rapid screening for co-infection of HIV and HCV in pregnant women in Benin City, Edo State, Nigeria.

33 A Call to Action: HCV Treatment of People Who Inject Drugs in the United States

34 What is required for achieving HCV elimination in Singapore? A modeling study

35 Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services

36 HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection

37 Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services

38 Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors

39 Boceprevir for untreated chronic HCV genotype 1 infection

40 dsrna-dependent protein kinase pkr and its role in stress, signaling and hcv infection

41 glances in immunology of hiv and hcv infection

42 on-treatment elevation in hepatic transaminases during hcv treatment with ombitasvir, paritaprevir, dasabuvir, ritonavir, and ribavirin: a case series

43 hiv and hcv coinfection: prevalence, associated factors and genotype characterization in the midwest region of brazil

44 an update on small molecule inhibitors of the hcv ns5b polymerase: effects on rna synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies

45 hepatocyte turnover in chronic hcv-induced liver injury and cirrhosis

46 parv4 prevalence, phylogeny, immunology and coinfection with hiv, hbv and hcv in a multicentre african cohort [version 1; referees: 2 approved]

47 mechanism of hcv's resistance to ifn-α in cell culture involves expression of functional ifn-α receptor 1

48 carpal tunnel syndrome in hiv-positive patients coinfected with hcv

49 are hiv, hbv and hcv voluntary counseling and testing programs needed in balkans?

50 a new sampling method for spleen stiffness measurement based on quantitative acoustic radiation force impulse elastography for noninvasive assessment of esophageal varices in newly diagnosed hcv-related cirrhosis

51 analysis of association between different hcv genotypes and serum interleukin-17, interleukin-6, and vitamin d in patients with hcv-related cirrhosis

52 neutralizing activities of caprine antibodies towards conserved regions of the hcv envelope glycoprotein e2

53 the humoral immune response to hcv: understanding is key to vaccine development

54 demethylase jmjd6 as a new regulator of interferon signaling: effects of hcv and ethanol metabolism

55 liver damage in patients with hcv/hiv coinfection is linked to hiv-related oxidative stress

56 genotyping of hcv rna reveals that 3a is the most prevalent genotype in mardan, pakistan

57 immunity and fibrogenesis: the role of th17/il-17 axis in hbv and hcv-induced chronic hepatitis and progression to cirrhosis

58 human leukocyte antigen class ii alleles (dqb1 and drb1) as predictors for response to interferon therapy in hcv genotype 4

59 influence of hiv and hcv on t cell antigen presentation and challenges in the development of vaccines

60 homa-ad in assessing insulin resistance in lean noncirrhotic hcv outpatients

61 role of anti-mutated citrullinated vimentin antibodies in chronic hepatitis c patients and its relation to hcv associated arthritis

62 association between phase angle, anthropometric measurements, and lipid profile in hcv-infected patients

63 potential of g-csf supplementation to counter the neutrophil effects of standard peg-ifnα plus ribavirin combination therapy for treating hcv-related cirrhosis

64 nk cell function and receptor diversity in the context of hcv infection

65 circulating mirnas as predictor markers for activation of hepatic stellate cells and progression of hcv-induced liver fibrosis

66 alteration of n-glycans and expression of their related glycogenes in the epithelial-mesenchymal transition of hcv29 bladder epithelial cells

67 [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]

68 Epidemiology and natural history of HCV infection - Nature Reviews Gastroenterology & Hepatology

69 Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

70 Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

71 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

72 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

73 Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology

74 Acute hepatitis B in patients with or without underlying chronic HCV infection

75 Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens

76 Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

77 Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

78 Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

79 Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan

80 Structural and compositional segregation of the gut microbiota in HCV and liver cirrhotic patients: A clinical pilot study.

Keyword Connections

Journals

Research Groups

Bibliographies